Tacrolimus (FK-506)

Drug Therapy in Dermatology

Volumn , Issue , 2016, Pages 161-170

  Contreras Ruiz, Jose ^a   Kerdel, Francisco A ^b  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69049113028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14006-12     Document Type: Chapter

References (29)

1. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK 506) ointment for atopic dermatitis:a phase I study in adults and children. J Am Acad Dermatol 1998; 38:69-76.
2. Lauerma A, Maibach H, Graunlund H, et al. Inhibition of contact allergy reactions by topical FK506. Lancet 1992; 340:556.
3. D’Inca R. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporin. Ann Intern Med 1998; 128:783-4.
4. Kawashima M, Nakagawa H, Ohtsuki, et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996; 348:1240-1241.
5. Ruzika T, Bieber T, Erwin Schöpf, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337(12): 816-821.
6. Aoyama H, Tabata N, Tanaka M, et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995; 133:492-500.
7. The European FK506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double blind, placebo-controlled study. Arch Dermatol 1996; 132:419-423.
8. Nikolaidis N, Abu-Elmagd K, Thomson H, et al. Metabolic effects of FK506 in patients with severe psoriasis: short-term follow-up of seven cases. Transplant Proc 1991; 23:3325-3327.
9. Zonneveld I, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic-plaque psoriasis. A pilot study. Arch Dermatol 1998; 134:1101-1102.
10. Abu-Elmagd K, Jegasothy B, Ackerman A, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc 1991; 23:3328-3329.
11. Fujita T, Takahashi S, Yagihashi A, et al. Prolonged survival of rat skin allograft by treatment with FK506 ointment. Transplantation 1997; 64:922-925.
12. Inamura N, Nakahara K, Kino T, et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation 1988; 45:206.
13. Wada H, Monden M, Gotoh M, et al. An attempt to induce tolerance to skin grafts in congenic mice with FK506. Transplant Proc 1991; 23:3280.
14. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effects of FK506 in vitro. J Antibiot 1987; 40:1256-1265.
15. Sawada S, Suzuki G, Kawase Y, et al. Novel immunosuppressive agent, FK 506:in vitro effects on the cloned T cell activation. J Immunol 1987; 139:1797-1803.
16. Griffith J, Kim J, Kim E, et al. X-ray structure of calcineurin inhibited by the immunophilin- immunosuppressant FKBP12-FK506 complex. Cell 1995; 82:507-522.
17. Meingassner J and Stütz A. Immunosuppressive Macrolides of the Type FK 506:A Novel Class of Topical Agents for Treatment of Skin Diseases? J Invest Dermatol 1992; 98:851-855.
18. Hooks M. Tacrolimus, a new immunosuppressant-a review of the literature. Ann Pharmacother 1994; 28:501-510.
19. Venkataramanan R, Jain A, Warty K, et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991; 23:2736-2740.
20. Fung J, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991; 23:14-21.
21. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344:883.
22. Nagai H, Hiyama H, Matsuo A, et al. FK-506 and cyclosporin-A potentiate the IgE antibody production by contact sensitization with hapten in mice. J Pharmacol Exp Ther 1997; 283:321-327.
23. Yamamoto S, Hong J, and Ryuchi K. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol 1994; 102:160-164.
24. McElwee K, Rushton D, Trachy R, et al. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br J Dermatol 1997; 137:491-497.
25. Schuppe H. Topical tacrolimus for pyoderma gangrenosum. Lancet 1998; 352:832.
26. Thomson A. FK 506-how much potential? Immunol Today 1989; 10:6-9.
27. Yoshimura N, Matsui S, Hamashima T, et al. Effect of a new immunosuppressive agent, FK 506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells as well as induction of alloreactivity. Transplantation 1989; 47:351-356.
28. Jain A, Fung J, Tzakis A, et al. Comparative study of cyclosporin and FK506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant Proc 1991; 23:2763-2766.
29. Kershner R and Fitzsimmons W. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62:920-926.